AstraZeneca AB Announces First Direct-to-Patient Program Offering the Brand ARIMIDEX┬« (anastrozole) Tablets to Patients for Only $40 Per Month  
2/16/2012 8:13:17 AM

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.